The Treatment of Mild and Moderate Asthma in Adults.
暂无分享,去创建一个
[1] M. Lommatzsch. Immune Modulation in Asthma: Current Concepts and Future Strategies , 2020, Respiration.
[2] C. Janson,et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme , 2020, European Respiratory Journal.
[3] J. Hoving,et al. Workplace interventions for treatment of occupational asthma , 2011, TBV – Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde.
[4] N. Kearns,et al. Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma , 2020, European Respiratory Journal.
[5] J. Virchow,et al. Perspectives in allergen immunotherapy: 2019 and beyond , 2019, Allergy.
[6] J. Virchow,et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials , 2019, The Lancet.
[7] R. Hancox,et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial , 2019, The Lancet.
[8] I. Pavord,et al. Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. , 2019, American journal of respiratory and critical care medicine.
[9] A. Sheikh,et al. GINA 2019: a fundamental change in asthma management , 2019, European Respiratory Journal.
[10] I. Pavord,et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. , 2019, The New England journal of medicine.
[11] O. Usmani. Choosing the right inhaler for your asthma or COPD patient , 2019, Therapeutics and clinical risk management.
[12] Xiaohui Xie,et al. Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis , 2019, The Journal of asthma : official journal of the Association for the Care of Asthma.
[13] J. Virchow,et al. Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma , 2018, Thorax.
[14] W. Busse,et al. Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma. , 2018, Respiratory medicine.
[15] W. Busse,et al. Combined Analysis of Asthma Safety Trials of Long‐Acting β2‐Agonists , 2018, The New England journal of medicine.
[16] E. Bateman,et al. Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma , 2018, The New England journal of medicine.
[17] C. White,et al. Association of Inhaled Corticosteroids and Long-Acting &bgr;-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis , 2018, JAMA.
[18] O. Usmani,et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes , 2018, Respiratory Research.
[19] Richard Beasley,et al. After asthma: redefining airways diseases , 2017, The Lancet.
[20] T. H. Nguyen,et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Respiratory medicine.
[21] A. von Leupoldt,et al. [Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]. , 2017, Pneumologie.
[22] J. Weiler,et al. Exercise-induced bronchoconstriction update-2016. , 2016, The Journal of allergy and clinical immunology.
[23] E. Bateman,et al. Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. , 2015, The Journal of allergy and clinical immunology.
[24] J. Virchow,et al. Severe asthma: definition, diagnosis and treatment. , 2014, Deutsches Arzteblatt international.
[25] M. Sears. Trends in the prevalence of asthma. , 2014, Chest.
[26] F. Ducharme,et al. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. , 2014, The Cochrane database of systematic reviews.
[27] R. Schmitz,et al. Häufigkeit allergischer Erkrankungen in Deutschland , 2013, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.
[28] Teresa To,et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey , 2012, BMC Public Health.
[29] Margaret W Leigh,et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.
[30] C. Jenkins,et al. Measuring asthma control: a comparison of three classification systems , 2010, European Respiratory Journal.
[31] T. Lasserson,et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. , 2010, The Cochrane database of systematic reviews.
[32] D. Sin,et al. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. , 2006, European journal of pharmacology.
[33] F. Ram,et al. Physical training for asthma , 2014, Sao Paulo medical journal = Revista paulista de medicina.
[34] P. Gibson,et al. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. , 2003, The Cochrane database of systematic reviews.
[35] J. Kips,et al. Cytokines in asthma , 2001, European Respiratory Journal.
[36] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .